CD4 and melanoma: In a B16 melanoma mouse model, CD11b+ DCs—the homolog of cDC2s in humans—infiltrate the tumor site but display a reduced antigen presentation capacity through MHC-II, causing a weak activation of CD4+ T-cells in lymph nodes [70].